blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2970908

EP2970908 - THERAPEUTIC PEPTIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.10.2020
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  22.11.2019
FormerGrant of patent is intended
Status updated on  15.11.2019
FormerExamination is in progress
Status updated on  06.11.2019
FormerGrant of patent is intended
Status updated on  16.06.2019
FormerExamination is in progress
Status updated on  14.02.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Dana-Farber Cancer Institute, Inc.
450 Brookline Avenue
Boston, MA 02215-5450 / US
[2016/03]
Inventor(s)01 / WUCHERPFENNIG, Kai, W.
67 Highland Road
Brookline, MA 02445 / US
02 / DRANOFF, Glenn
150 Concord Road
Sudbury, MA 01776 / US
03 / HODI, F., Stephen
15 Vaillencourt Drive
Framingham, MA 02115 / US
04 / FRANZ, Bettina
9 Sherman House
Rustat Avenue
Cambridge MA CB1 3RF / GB
05 / MAY, Kenneth, F.
106 Village Downtown Blvd.
Bozeman, MT 59715 / US
06 / HARVEY, Christopher
8 Conway Street
Boston, MA 02131 / US
 [2016/03]
Representative(s)Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
[N/P]
Former [2016/03]Reitstötter Kinzebach
Patentanwälte
Sternwartstrasse 4
81679 München / DE
Application number, filing date14720000.014.03.2014
[2016/03]
WO2014US29348
Priority number, dateUS201361792034P15.03.2013         Original published format: US 201361792034 P
US201361913198P06.12.2013         Original published format: US 201361913198 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2014144791
Date:18.09.2014
Language:EN
[2014/38]
Type: A2 Application without search report 
No.:EP2970908
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2970908
Date:25.12.2019
Language:EN
[2019/52]
Search report(s)International search report - published on:EP27.11.2014
ClassificationIPC:A61K38/12, C12N5/0783, A61K39/395, A61K35/14, C07K16/28, A61K39/00, A61K38/15, A61N5/10, A61K45/06, A61K35/17, C07K16/30
[2018/52]
CPC:
C07K16/2833 (EP,US); A61K38/12 (EP,US); A61K38/15 (EP,US);
A61K39/39558 (EP,US); A61K39/4613 (EP); A61K39/4644 (EP);
A61K45/06 (EP,US); A61N5/10 (US); A61P35/00 (EP);
C07K16/30 (US); C07K16/3015 (US); C07K16/3023 (US);
C07K16/3053 (US); C07K16/3061 (US); C07K16/3069 (US);
A61K2039/505 (EP,US); A61K35/17 (US); C07K2317/21 (EP,US);
C07K2317/34 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (US);
C07K2317/567 (US); C07K2317/73 (EP,US); C07K2317/92 (EP,US) (-)
C-Set:
A61K38/15, A61K2300/00 (US,EP);
A61K39/39558, A61K2300/00 (EP,US)
Former IPC [2016/03]C12N5/0783, A61K39/395, A61K35/14, C07K16/28, A61K39/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBA07.10.2015
ME07.10.2015
TitleGerman:THERAPEUTISCHE PEPTIDE[2016/03]
English:THERAPEUTIC PEPTIDES[2016/03]
French:PEPTIDES THÉRAPEUTIQUES[2016/03]
Entry into regional phase07.10.2015National basic fee paid 
07.10.2015Designation fee(s) paid 
07.10.2015Examination fee paid 
Examination procedure07.10.2015Examination requested  [2016/03]
02.05.2016Amendment by applicant (claims and/or description)
07.10.2016Despatch of a communication from the examining division (Time limit: M08)
07.07.2017Reply to a communication from the examining division
26.10.2017Despatch of a communication from the examining division (Time limit: M04)
27.02.2018Reply to a communication from the examining division
29.03.2018Despatch of a communication from the examining division (Time limit: M04)
11.07.2018Reply to a communication from the examining division
29.11.2018Despatch of a communication from the examining division (Time limit: M04)
12.12.2018Reply to a communication from the examining division
17.06.2019Communication of intention to grant the patent
28.10.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
28.10.2019Fee for grant paid
28.10.2019Fee for publishing/printing paid
14.11.2019Information about intention to grant a patent
14.11.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19207376.5  / EP3666886
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  07.10.2016
Opposition(s)28.09.2020No opposition filed within time limit [2020/49]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
07.07.2017Request for further processing filed
07.07.2017Full payment received (date of receipt of payment)
Request granted
19.07.2017Decision despatched
Fees paidRenewal fee
10.03.2016Renewal fee patent year 03
10.03.2017Renewal fee patent year 04
27.03.2018Renewal fee patent year 05
27.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.03.2014
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MK25.12.2019
MT25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
IE14.03.2020
LU14.03.2020
BG25.03.2020
NO25.03.2020
GR26.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
IS25.04.2020
PT20.05.2020
[2022/32]
Former [2022/27]HU14.03.2014
AL25.12.2019
AT25.12.2019
CY25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
MT25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
TR25.12.2019
IE14.03.2020
LU14.03.2020
BG25.03.2020
NO25.03.2020
GR26.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
IS25.04.2020
PT20.05.2020
Former [2021/11]AL25.12.2019
AT25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
NL25.12.2019
PL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
IE14.03.2020
LU14.03.2020
BG25.03.2020
NO25.03.2020
GR26.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
IS25.04.2020
PT20.05.2020
Former [2021/07]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
IE14.03.2020
LU14.03.2020
BG25.03.2020
NO25.03.2020
GR26.03.2020
CH31.03.2020
LI31.03.2020
IS25.04.2020
PT20.05.2020
Former [2021/04]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
LU14.03.2020
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/50]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
MC25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SI25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/47]AL25.12.2019
CZ25.12.2019
DK25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/40]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
IS25.04.2020
PT20.05.2020
Former [2020/37]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
SK25.12.2019
SM25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
PT20.05.2020
Former [2020/36]AL25.12.2019
CZ25.12.2019
EE25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
PT20.05.2020
Former [2020/35]AL25.12.2019
CZ25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RO25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/32]AL25.12.2019
FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
NL25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/25]FI25.12.2019
HR25.12.2019
LT25.12.2019
LV25.12.2019
RS25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/23]FI25.12.2019
LT25.12.2019
LV25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
GR26.03.2020
Former [2020/22]FI25.12.2019
LT25.12.2019
SE25.12.2019
BG25.03.2020
NO25.03.2020
Former [2020/21]NO25.03.2020
Cited inInternational search[XP]WO2013049517  (DANA FARBER CANCER INST INC [US]);
by applicantEP0154316
 WO8807054
 WO8807089
 EP0401384
 US5122464
 US5225539
 WO9429351
 US5530101
 WO9632478
 US5585089
 US5591639
 US5624821
 US5648260
 US5658759
 WO9734631
 US5677425
 US5693762
 US5714350
 US5869046
 WO9951642
 WO9954342
 US5981216
 WO0042072
 US6121022
 US6165745
 US6180370
 US6194551
 WO0158957
 US6277375
 WO0206919
 EP1176195
 US6350861
 US2003022450
 WO03035835
 US2003153043
 WO03074679
 WO2004016750
 US2004067503
 WO2004029207
 WO2004035752
 US6737056
 WO2004063351
 WO2004074455
 WO2004099249
 WO2005040217
 WO2005070963
 WO2005092925
 WO2006020114
 US7317091
 US2010261269
 US8101720
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.